1. Academic Validation
  2. W2476 ameliorates β-cell dysfunction and exerts therapeutic effects in mouse models of diabetes via modulation of the thioredoxin-interacting protein signaling pathway

W2476 ameliorates β-cell dysfunction and exerts therapeutic effects in mouse models of diabetes via modulation of the thioredoxin-interacting protein signaling pathway

  • Acta Pharmacol Sin. 2017 Jul;38(7):1024-1037. doi: 10.1038/aps.2017.15.
Ting Li 1 2 Guang-Yao Lin 2 3 Li Zhong 1 2 Yan Zhou 1 Jia Wang 1 Yue Zhu 1 2 Yang Feng 1 Xiao-Qing Cai 1 Qing Liu 1 Olivier Nosjean 4 Jean A Boutin 4 Pierre Renard 4 De-Hua Yang 1 2 Ming-Wei Wang 1 2 3 4 5
Affiliations

Affiliations

  • 1 The National Center for Drug Screening and the CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • 2 University of Chinese Academy of Sciences, Beijing 100049, China.
  • 3 School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.
  • 4 Pôle d'Expertise Biotechnologie, Chimie et Biologie, Institut de Recherches SERVIER, Croissy-sur-Seine 78290, France.
  • 5 School of Pharmacy, Fudan University, Shanghai 201203, China.
Abstract

Recent evidence shows that high glucose levels recruit carbohydrate response element-binding protein, which binds the promoter of thioredoxin-interacting protein (txnip), thereby regulating its expression in β-cells. Overexpression of txnip not only induces β-cell Apoptosis but also reduces Insulin production. Thus, the discovery of compounds that either inhibit TXNIP activity or suppress its expression was the focus of the present study. INS-1E cells stably transfected with either a txnip proximal glucose response element connected to a luciferase reporter plasmid (BG73) or full-length txnip promoter connected to a luciferase reporter plasmid (CL108) were used in primary and secondary high-throughput screening campaigns, respectively. From 256 000 synthetic compounds, a small molecule compound, W2476 [9-((1-(4-acetyl-phenyloxy)-ethyl)-2-)adenine], was identified as a modulator of the TXNIP-regulated signaling pathway following the screening and characterized using a battery of bioassays. The preventive and therapeutic properties of W2476 were further examined in streptozotocin-induced diabetic and diet-induced obese mice. Treatment with W2476 (1, 5, and 15 μmol/L) dose-dependently inhibited high glucose-induced TXNIP expression at the mRNA and protein levels in INS-1E cells and rat pancreatic islets. Furthermore, W2476 treatment prevented INS-1E cells from Apoptosis induced by chronic exposure of high glucose and enhanced Insulin production in vitro. Oral administration of W2476 (200 mg·kg-1·d-1) rescued streptozotocin-induced diabetic mice by promoting β-cell survival and enhancing Insulin secretion. This therapeutic property of W2476 was further demonstrated by its ability to improve glucose homeostasis and Insulin sensitivity in diet-induced obese mice. Thus, chemical intervention of the TXNIP-regulated signaling pathway might present a viable approach to manage diabetes.

Figures
Products